through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 783–3238.

Dated: March 15, 1995.

Linda Rosenstock,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–6861 Filed 3–20–95; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

[Docket No. 95G–0039]

Degussa Corp.; Filing of Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Degussa Corp. has filed a petition (GRAS 2419) proposing that hydrophobic silica, prepared by the hydrophobization of silicon dioxide with dichlorodimethyl-silane, be affirmed as generally recognized as safe (GRAS) as an anticaking/free-flow agent in vitamin preparations for animal feed.

DATES: Written comments by June 5, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: J. D. McCurdy, Center for Veterinary Medicine (HFV–226), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1731.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 201(s), 409(b)(5) (21 U.S.C. 321(s) and 348(b)(5)) and the regulations for affirmation of GRAS status in § 570.35 (21 CFR 570.35), notice is given that Degussa Corp., c/o Counsel for Petitioner, Jerome H. Heckman, Keller, and Heckman, 1001 G St. NW., Suite 500 West, Washington, DC 20001, has filed a petition (GRASP 2419) proposing that hydrophobic silica, prepared by the hydrophobization of silicon dioxide with dichlorodimethyl-silane, be affirmed as GRAS as an anticaking/free-flow agent in vitamin preparations for animal feed.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in §§ 570.30 (21 CFR 570.30) and 570.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Interested persons may, on or before June 5, 1995, review the petition and file comments with the Dockets Management Branch (address above). Two copies of any comments should be filed and should be identified with the docket number found in brackets in the heading of this document. Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. In addition, consistent with the regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency encourages public participation by review of and comment on the environmental assessment submitted with the petition that is the subject of this notice. A copy of the petition (including the environmental assessment) and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 8, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95–6918 Filed 3–20–95; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Arthritis Advisory Committee. This meeting was announced in the **Federal Register** of February 17, 1995 (60 FR 9338). This amendment is being made to announce the cancellation of the open committee discussion portion of the meeting and adjustment of the starting time. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Isaac F. Roubein, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Arthritis Advisory Committee, code 12532.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 17, 1995 (60 FR 9338), FDA announced that the Arthritis Advisory Committee would hold a meeting on March 27, 1995.

On page 9338, column 2, the ''*Date, time, and place*'' portion is amended to read as follows:

Date, time, and place. March 27, 1995, 9 a.m., Holiday Inn—Silver Spring, Silver Room, 8777 Georgia Ave., Silver Spring, MD.

On page 9338, column 2, the ''*Type of meeting and contact person*'' portion is amended to read as follows:

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m., unless public participation does not last that long; closed committee deliberations, 10 a.m. to 4 p.m.; Isaac F. Roubein, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Arthritis Advisory Committee, code 12532.

Dated: March 16, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–7068 Filed 3–17–95; 3:46 pm]

BILLING CODE 4160–01–F

Advisory Committee Meetings; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Nonprescription Drugs Advisory Committee. This meeting was announced in the **Federal Register** of February 17, 1995 (60 FR 9335 at 9336). The amendment is being made to announce the cancellation of the joint session with the Dermatologic and Ophthalmic Drugs Advisory Committee; the cancellation of the session with